XML 45 R24.htm IDEA: XBRL DOCUMENT v3.3.1.900
Earnings Per Share
 12 Months Ended
Oct. 31, 2015
Earnings Per Share [Abstract]  
Earnings Per Share
Note 16. Earnings Per Share
Basic earnings (loss) per common share (“EPS”) are generally calculated as income (loss) available to common shareholders divided by the weighted average number of common shares outstanding. Diluted EPS is generally calculated as income (loss) available to common shareholders divided by the weighted average number of common shares outstanding plus the dilutive effect of common share equivalents.
The calculation of basic and diluted EPS for the years ended October 31, 2015, 2014 and 2013 was as follows:
 
 
2015
 
2014
 
2013
Numerator
 
 
 
 
 
 
Net loss
 
$
(29,684
)
 
$
(38,883
)
 
$
(35,319
)
Net loss attributable to noncontrolling interest
 
325

 
758

 
961

Preferred stock dividend
 
(3,200
)
 
(3,200
)
 
(3,200
)
Net loss attributable to common shareholders
 
$
(32,559
)
 
$
(41,325
)
 
$
(37,558
)
Denominator
 
 
 
 
 
 
Weighted average basic common shares
 
24,513,731

 
20,473,915

 
15,543,750

   Effect of dilutive securities (1)
 
—

 
—

 
—

Weighted average diluted common shares
 
24,513,731

 
20,473,915

 
15,543,750

   Basic loss per share
 
(1.33
)
 
(2.02
)
 
(2.42
)
   Diluted loss per share (1)
 
(1.33
)
 
(2.02
)
 
(2.42
)
(1)
Due to the net loss to common shareholders in each of the years presented above, diluted earnings per share was computed without consideration to potentially dilutive instruments as their inclusion would have been antidilutive. Potentially dilutive instruments include stock options, warrants, unvested RSAs and RSUs and convertible preferred stock. At October 31, 2015, 2014 and 2013, there were options to purchase 0.3 million shares of common stock. At October 31, 2015, 2014 and 2013, respectively, there were warrants to purchase 0.2 million, 0.5 million and 0.4 million shares of common stock, which were not included in the calculation of diluted earnings per share as they would be antidiulutive.